ArticleInflammopharmacology2025
Evaluating pomegranate seed oil for potential topical applications: safety, anti-inflammatory activity and wound healing in skin cell models.
Article in Inflammopharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pomegranate seed oil attenuates palmitic acid-induced hepatic injury through modulation of oxidative stress: insights from GC-Q-TOF-MS-based metabolomics.Journal of the science of food and agriculture · 2026Article
- Bioactive Aromatic Plant Extracts Modulate Metabolism and Inflammation in HeLa Cells.Molecules (Basel, Switzerland) · 2025Article
- Ozone therapy for temporomandibular joint osteoarthritis: a comment on the mechanistic insights and clinical translation.Inflammopharmacology · 2025Article
- Joint disorders and ozone therapy: some comments.Inflammopharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Pomegranate seed oil (PSO), a by-product of pomegranate juice production, has a long-standing role in traditional medicine, yet is mechanistic and pharmaceutical potential for skin applications remains unexplored. This work explored the bioactivity of PSO in human keratinocytes (HaCaT) and dermal fibroblasts (HDFa) through evaluation of its impact upon cellular metabolism, anti-inflammatory properties and wound healing capacity. The data obtained showed that PSO exhibited no cytotoxic effects up to 500 µg/mL and significantly suppressed pro-inflammatory cytokines (IL-6, IL-8, TNF-α) under LPS-induced inflammatory conditions. Furthermore, wound closure in fibroblasts was accelerated by approximately 20% in a 24-h period. Although antioxidant activity was limited under induced oxidative stress, PSO exerted mild protective effects under basal conditions and fatty acid profiling revealed a PUFA-rich composition, including dihomolinolenic and punicic acids, potentially linked to the observed impact upon cellular metabolism. Overall, these findings offer novel insights into PSO's dual functionality in skin regeneration and immune modulation, supporting its application as a bioactive ingredient for advanced topical therapies.
Indexed as
Identifiers
41065959What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.